Article info
Original research
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
- Correspondence to Dr Yusuf Ilhan, Department of Medical Oncology, Akdeniz University, Antalya, Turkey; dryusufilhan{at}gmail.com
Citation
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
Publication history
- Received October 4, 2021
- Accepted January 13, 2022
- First published January 27, 2022.
Online issue publication
June 01, 2022
Article Versions
- Previous version (4 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.